Woodline Partners’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-317,587
| Closed | -$33.9M | – | 1125 |
|
|
2025
Q3 | $33.9M | Buy |
317,587
+16,760
| +6% | +$1.75M | 0.16% | 178 |
|
|
2025
Q2 | $28.5M | Hold |
300,827
| – | – | 0.15% | 206 |
|
|
2025
Q1 | $19.1M | Sell |
300,827
-215,778
| -42% | -$12.9M | 0.12% | 234 |
|
|
2024
Q4 | $24M | Buy |
516,605
+8,660
| +2% | +$325K | 0.16% | 181 |
|
|
2024
Q3 | $14.6M | Buy |
507,945
+6,747
| +1% | +$166K | 0.12% | 231 |
|
|
2024
Q2 | $7.25M | Sell |
501,198
-338,569
| -40% | -$4.94M | 0.07% | 290 |
|
|
2024
Q1 | $13.5M | Buy |
839,767
+338,802
| +68% | +$5.86M | 0.12% | 224 |
|
|
2023
Q4 | $9.96M | Sell |
500,965
-85,757
| -15% | -$1.27M | 0.11% | 229 |
|
|
2023
Q3 | $9.56M | Buy |
586,722
+86,722
| +17% | +$1.67M | 0.11% | 230 |
|
|
2023
Q2 | $10.6M | Sell |
500,000
-1,244,264
| -71% | -$26.5M | 0.13% | 204 |
|
|
2023
Q1 | $35M | Buy |
1,744,264
+1,494,264
| +598% | +$32.3M | 0.48% | 53 |
|
|
2022
Q4 | $6.53M | Sell |
250,000
-125,033
| -33% | -$1.66M | 0.09% | 273 |
|
|
2022
Q3 | $3.83M | Sell |
375,033
-126,425
| -25% | -$1.07M | 0.05% | 345 |
|
|
2022
Q2 | $2.1M | Buy |
+501,458
| New | +$2.14M | 0.03% | 415 |
|
Other funds holding VRNA
Woodline Partners's VRNA Position: Q4 2025 in Review
Woodline Partners sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 317,587 shares — an estimated $33.9M sold.
Woodline Partners first reported a position in VRNA in Q2 2022 and held it in 14 quarters. The position peaked at $35M in Q1 2023. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Woodline Partners reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Woodline Partners sold 317,587 Verona Pharma shares in Q4 2025, an estimated $33.9M.
- Woodline Partners first reported a position in Verona Pharma in Q2 2022 and held it in 14 quarters.
- Woodline Partners's Verona Pharma position peaked at $35M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.